Antipsychotic Agents
Bipolar Disorder
Lurasidone Hydrochloride
Schizophrenia

Lurasidone

Lurasidone is a second-generation (atypical) antipsychotic in the benzisothiazole class, indicated for the treatment of schizophrenia and bipolar depression. The drug has a distinct receptor-binding profile that differentiates it from other antipsychotics. This activity provides a comprehensive understanding of the complex pharmacology, FDA-approved indications, mechanism of action, contraindications, boxed warnings, adverse effects, dosing, monitoring, and drug interactions of lurasidone. Emphasis is placed on evidence-based strategies to optimize treatment outcomes, minimize adverse events, and deliver patient-centered care in both monotherapy and adjunctive treatment settings. This activity provides healthcare professionals with essential knowledge and practical tools for the safe and effective use of lurasidone, underscoring their critical role in supporting patient care. By combining pharmacologic knowledge with collaborative practice, interprofessional healthcare providers can collaborate to individualize therapy, enhance safety, and improve clinical outcomes. This training enables healthcare professionals to apply evidence-based medicine effectively, maximize the therapeutic benefits of lurasidone, mitigate risks, and work efficiently within a coordinated healthcare team.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.